Shlipak M G, Browner W S, Noguchi H, Massie B, Frances C D, McClellan M
Medical Service, Veterans Affairs Medical Center, University of California, San Francisco 94121, USA.
Am J Med. 2001 Apr 15;110(6):425-33. doi: 10.1016/s0002-9343(01)00652-0.
Angiotensin converting-enzyme (ACE) inhibitors decrease mortality after myocardial infarction among patients with depressed left ventricular function. Beta blockers may also improve survival in these patients. We compared the relative effects of these agents on the survival of elderly patients with a left ventricular ejection fraction less than 40% after myocardial infarction.
The Cooperative Cardiovascular Project collected data on patients aged 65 years and older who were admitted with myocardial infarction from April 1994 to July 1995, including 20,902 with a measured left ventricular ejection fraction less than 40% before discharge. Using proportional hazard regression models that adjusted for patient characteristics and in-hospital treatments, we compared survival among patients discharged on ACE inhibitors, beta blockers, both medications, or neither medication.
Among patients surviving hospitalization with reduced left ventricular function, 9,108 (44%) were discharged on ACE inhibitors, 2,613 (13%) on beta blockers, 3,309 (16%) on both medications, and 5,872 (28%) on neither medication. Patients treated with ACE inhibitors were more likely to have a prior diagnosis of heart failure and less likely to have undergone revascularization, whereas those treated with beta blockers were more often treated with thrombolytic therapy and aspirin. Patients treated with ACE inhibitors [hazard ratio (HR = 0.80), 0.80; 95% confidence interval (CI), 0.73 to 0.87] or beta blockers (HR = 0.76, 0.76; 95% CI, 0.64 to 0.90) had lower adjusted 1-year mortality than those who were not treated with either medication. The combination of both medications was associated with additional benefit (HR = 0.68, 0.68; 95% CI, 0.59 to 0.80). The relative benefit of each medication was greatest among patients with an ejection fraction less than 30%, a serum creatinine level 2.0 mg/dL or greater, or both. To prevent a death within a year, the number of patients who needed to be treated with both medications varied from 5 to 15, depending on ejection fraction and renal function.
ACE inhibitors and beta blockers were associated with similar improvements in survival among elderly patients with reduced left ventricular ejection fraction after myocardial infarction. Our results suggest that patients who can tolerate both medications gain additional benefit from the combination.
血管紧张素转换酶(ACE)抑制剂可降低左心室功能不全患者心肌梗死后的死亡率。β受体阻滞剂也可能改善这些患者的生存率。我们比较了这些药物对心肌梗死后左心室射血分数低于40%的老年患者生存率的相对影响。
合作心血管项目收集了1994年4月至1995年7月因心肌梗死入院的65岁及以上患者的数据,其中包括20902例出院前左心室射血分数测量值低于40%的患者。使用针对患者特征和住院治疗进行调整的比例风险回归模型,我们比较了出院时使用ACE抑制剂、β受体阻滞剂、两种药物或两种药物都未使用的患者的生存率。
在左心室功能降低且存活出院的患者中,9108例(44%)出院时使用ACE抑制剂,2613例(13%)使用β受体阻滞剂,3309例(16%)使用两种药物,5872例(28%)两种药物都未使用。接受ACE抑制剂治疗的患者更可能既往有心力衰竭诊断,且接受血运重建的可能性较小,而接受β受体阻滞剂治疗的患者更常接受溶栓治疗和阿司匹林治疗。接受ACE抑制剂治疗的患者[风险比(HR)=0.80,0.80;95%置信区间(CI),0.73至0.87]或β受体阻滞剂治疗(HR =